NCT00118365View on ClinicalTrials.gov

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

PHASE3CompletedINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

July 31, 1998

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Precancerous Condition
Interventions
OTHER

placebo

Given orally

DRUG

eflornithine

Given orally

DRUG

sulindac

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

92868

University of California Medical Center At Irvine-Orange Campus, Orange

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00118365 - Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps | Biotech Hunter | Biotech Hunter